drugset / Trial / NCT01949662

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

NCT01949662

RandomizedParallel-groupDouble-blindSupportive care

Summary

This randomized phase II trial studies how well haloperidol with or without lorazepam works in reducing confusion, disorientation, and inability to think or remember clearly (delirium) in patients with cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Palliative therapy with haloperidol and lorazepam may reduce symptoms of delirium and help patients with advanced cancer live more comfortably. It is not yet known whether lorazepam may be an effective treatment for delirium when given with haloperidol.

Timeline

Start
2014-01
Primary completion
2016-08-26
Completion
2028-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lorazepam Small molecule 3 mg Intravenous
Background Haloperidol Decanoate Small molecule 8 mg Intravenous